Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
29.3.2023 15:00:00 EEST | Business Wire | Press release
Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments. This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer.
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for platinum-resistant ovarian cancer. ArsenalBio’s work to develop multi-functional CAR-T cell therapies is enabled by Thermo Fisher’s Cell Therapy Systems (CTS) portfolio of products, including the Gibco™ CTS™ Xenon™ Electroporation System and the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System.
“Our programmable cell therapy technology holds the potential to help patients with aggressive and complex cancers who currently have few treatment options,” said Ken Drazan, M.D., co-founder and chief executive officer, ArsenalBio. “To bring the promise of this technology to patients we’ll need to execute at speed and scale as we transition to clinical development. Our relationship with Thermo Fisher allows us to combine their fit-for-purpose solutions and internal expertise with our team’s innovative approach to clinical research and process development capabilities to manufacture ArsenalBio’s products and explore future therapeutic innovation.”
Thermo Fisher began its collaboration with ArsenalBio in 2020 to help ArsenalBio overcome challenges associated with cell therapy manufacturing by working together to support development of a clinical-scale gene editing process. In addition, ArsenalBio received early access to Thermo Fisher’s latest instrumentation and reagents.
“By collaborating with ArsenalBio as they pioneer a new approach to treat solid tumors using engineered T cell therapies, we’re helping bring more options to those who are most in need of innovative treatments,” said Betty Woo, vice president of cell, gene and advanced therapies, Thermo Fisher. “Through our Cell Therapy Collaboration Program, we are enabling the industry shift from reactive to proactive, applying our biological and technical expertise to improve the economics of therapy production, and moving toward expanded access to patients worldwide.”
Thermo Fisher’s CTS portfolio of products are cGMP manufactured, designed to meet applicable cell therapy standards, and include traceability and regulatory documentation to help customers transition from research to clinical production.
For more information about Thermo Fisher’s cell therapy collaboration partnership program, please visit thermofisher.com/collabcenterpartnership.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005043/en/
Contact information
Media:
Kristin Blake
Thermo Fisher Scientific
Phone: 760-637-1166
Email: kristin.blake@thermofisher.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Deepens Advisory Solutions in Turkey with ODS Consulting Group14.7.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm ODS Consulting Group, enhancing its platform across digital transformation, talent strategy, and operational advisory services. Founded in 2008 and headquartered in Turkey, ODS Consulting Group provides advisory services to organizations seeking growth, talent, and investment opportunities in Turkey and international markets. The firm supports clients through international business development and export consulting, recruitment and talent management solutions, and investment advisory services, helping businesses expand operations, access new markets, attract qualified talent, and navigate the Turkish business landscape. With a multidisciplinary approach and deep local expertise, ODS delivers tailored strategies that drive sustainable growth and long-term value creation. “Since our founding, we have focused on helping organizations build sustainable growth through a combination of strategic insight and practical execution,” said Onur Seçkin, c
IAMPHENOM Europe 2026 Speaker Lineup Focuses on Practitioners Redesigning HR Operations with AI, Agents and Automation14.7.2026 16:30:00 EEST | Press release
Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, today announced the first wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714617871/en/ Phenom today announced the first wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. At the two-day in-person event, HR professionals, talent acquisition and talent management leaders, HRIT teams and C-suite executives will experience unparalleled immersive AI learning and networking. Attendees will gain actionable strategies from the organisations already using agents and automation to improve work operations and strengthen hiring, development and retention, while connecting w
RealPage Acquires Cherre, Creating a Trusted AI-Powered Intelligence Platform Across the Full Real Estate Capital Stack14.7.2026 16:03:00 EEST | Press release
RealPage, Inc., a leading provider of AI-enabled software and data analytics to the real estate industry, today announced it has completed its acquisition of Cherre, a real estate data intelligence company trusted by institutional owners, investment managers, and operators worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714560587/en/ RealPage now with Cherre. "AI can transform real estate only if it understands real estate," said Dirk Wakeham, President and Chief Executive Officer of RealPage. "Cherre has built the kind of trusted, governed intelligence that institutional owners and asset managers depend on. Bringing that expertise into RealPage means every customer, whether they manage one property or a global portfolio, gets access to a stronger, more trustworthy foundation for their decisions.” "We've always believed real estate organizations can't make confident decisions on data alone. They need a trusted,
Statement on Terminating the Letter of Intent With AI Financial Corporation14.7.2026 16:00:00 EEST | Press release
Statement from Matthew Nicoletti, Chief Strategy Officer, Perpetuals.com (Nasdaq: PDC), on the proposed transaction with AI Financial Corporation. “Perpetuals has decided not to further pursue the acquisition of AI Financial Corporation’s subsidiary Alt5 Sigma Canada, Inc. and the earlier letter of intent has been terminated.” About Perpetuals.com Ltd Perpetuals.com Ltd (Nasdaq: PDC) is a fintech company developing AI-powered trading products and prediction markets, with a global footprint across the United States, Europe, and Asia. Its mission is to reduce risk through empowering retail users with intuitive, secure, and efficient trading experiences that span the world’s capital markets. UpsideOnly, the company's flagship consumer product, is the first risk-free trading platform, pairing human market insight with proprietary BayesShield AI so users can share in trading profits without ever risking their own money. Perpetuals’s proprietary AI system, BayesShield AI, combines advanced A
VIVERE Group Selects Rimini Street to Strengthen SAP Support and Accelerate Business Transformation14.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced VIVERE Group, a leading Indonesian one-stop solution provider for interior contracting, furniture manufacturing and furnishing, has selected Rimini Support™ for SAP to help maintain business continuity, strengthen support for its critical SAP ECC environment and free internal IT resources to focus on digital transformation initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714644251/en/ VIVERE Group Selects Rimini Street to Strengthen SAP Support and Accelerate Business Transformation Strengthening SAP support while advancing transformation Founded in 1984 and listed on the Indonesia Stock Exchange since 2002, PT Gema Graham Sarana Tbk (IDX: GEMA) has grown into the core company of VIVERE Group, running SAP ECC 6 on IBM Db2 as a crit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom